Interleukin-6: from basic science to medicine--40 years in immunology.

By T. Kishimoto. Annual Review of Immunology, 2005

1,067 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/71568f66e3a1862dcee61e897048dd20ece6d61f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Karin
2. V. Kuchroo
3. S. Grivennikov
4. T. Korn
5. Sivakumar Vallabhapurapu
6. S. Rose‐John
7. M. Oukka
8. J. Terzic

In Oncology

1. M. Karin
2. S. Grivennikov
3. S. Rose‐John
4. J. Massagué
5. D. Nguyen
6. X. Zhang
7. Larry Norton
8. Thordur Oskarsson

Citations in the corpus

• IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 (2012, background): “Since all cells in the body express gp130 [9, 10], theoretically, all cells can be activated by the IL-6/sIL-6R complex.”
• Tumor self-seeding by circulating cancer cells (2009, methodology): “of immune and inflammatory responses and have been implicated in tumor progression (Hodge et al., 2005; Kishimoto, 2005).”
• Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. (2007, background): “The IL-6 family cytokines, including IL-6, OSM, and LIF, share the same gp130signaling receptor, leading to activation of JAK1, JAK2, and Tyk2 and subsequent phosphorylation of STAT3 (21, 23).”
• Interleukin-6 in aging and chronic disease: a magnificent pathway. (2006, background): “Cardiac myxoma, a benign atrial heart tumor, produces large quantities of IL-6, which cause autoantibody production, fever, joint pain, and anemia (108).”
• IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer (2009, background): “By binding to its gp130-associated receptor, IL-6 activates three separate signaling pathways, namely Shp2-Ras-ERK, JAK1/2-Stat3, and PI3K-Akt-mTOR (Kishimoto, 2005).”
• IL-17 and Th17 Cells. (2009, background): “Depending on the cellular source of IL-6, cytokines such as IL-1, tumor necrosis factor (TNF), plateletderived growth factor (PDGF), IL-3, GMCSF, and IL-17 are important inducers of IL-6 (39, 40).”
• Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. (2008, background): “Interleukin-6 (IL-6) is a pleiotropic cytokine associated with the control and coordination of immune responses (Kishimoto, 2005).”
• Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis (2011, methodology): “Peripheral T cell blasts from a patient displayed normal STAT3 activation in response to IL-23, as shown by WB (Fig.”
• Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype (2010, background): “IL-6 is a potent activator of megakaryocyte survival, differentiation and platelet formatio”
• IL-6 in inflammation, immunity, and disease. (2014, neutral): “5) (Kishimoto 2005).”